Beam Therapeutics Inc. (BEAM) Stock Price & Analysis
Beam Therapeutics Inc. (BEAM) rose 2.32% to USD 30.47 as of June 10, 2026 at 00:28 UTC, according to Nexqual real-time market data.
BEAM last closed at USD 29.78; the session ranged USD 29–31.33 on volume of 1,536,794 shares. Market capitalization is $3.13B, with a 52-week range of USD 15.6–36.44 (NMS). Source: Nexqual, June 10, 2026 at 00:28 UTC.
Key Statistics (as of June 10, 2026 at 00:28 UTC)
| Price | USD 30.47 |
|---|---|
| Change | ▲ 2.32% (up) |
| Previous Close | USD 29.78 |
| Open | USD 30.79 |
| Day Range | USD 29 – 31.33 |
| 52-Week Range | USD 15.6 – 36.44 |
| Volume | 1,536,794 shares |
| Market Cap | $3.13B |
| Exchange | NMS |
Technical Analysis (BEAM)
Nexqual's technical model rates BEAM "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:28 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 50.05 (neutral) |
| vs SMA50 | Above (USD 29.2) |
| MACD | 0.32 (positive) |
Analyst Ratings (BEAM)
Wall Street analysts rate BEAM "Strong Buy" based on 15 analysts, with a mean price target of USD 51.07 (range USD 26–80), per Nexqual as of June 10, 2026 at 00:28 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 51.07 |
| High Target | USD 80 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 15 / 2 / 0 |
Earnings (BEAM)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1.13 |
| Revenue Estimate | $16.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.91 vs est -1.01 ▲ beat |
| 2025-12-31 | USD 2.33 vs est -1.12 ▲ beat |
| 2025-09-30 | USD -1.1 vs est -1.01 ▼ miss |
| 2025-06-30 | USD -1 vs est -1.09 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financials & Fundamentals (BEAM)
| Total Revenue | $164.01M |
|---|---|
| Revenue Growth (YoY) | +324.90% |
| Gross Margin | -146.90% |
| Operating Margin | -337.81% |
| Profit Margin | -40.23% |
| ROE | -5.77% |
| Debt / Equity | 21.54 |
| Current Ratio | 16.99 |
| Total Cash | $1.21B |
| Total Debt | $250.82M |
| Free Cash Flow | $-233.56M |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financial Health Score (BEAM)
Nexqual rates Beam Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:28 UTC.
| Growth | Strong — Revenue +120% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.21B cash vs $251M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$234M, burning cash |
| Efficiency | Critical — ROE -6%, ROA -15.8% |
Ownership (BEAM)
| Insider Ownership | +1.36% |
|---|---|
| Institutional Ownership | +107.03% |
| Shares Outstanding | 102.88M |
| Float | 87.97M |
| Short % of Float | +32.31% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Leadership (BEAM)
Beam Therapeutics Inc. is led by John M. Evans (age 47), CEO & Director, per Nexqual as of June 10, 2026 at 00:28 UTC.
| CEO & Director | John M. Evans (age 47) |
|---|---|
| President | Giuseppe Ciaramella (age 56) |
| Chief Financial Officer | Sravan Kumar Emany (age 47) |
| Chief Technology Officer | Manmohan Singh |
Major Backers & Investors (BEAM)
Notable institutional backers of Beam Therapeutics Inc. include ARK Invest, FMR, LLC, Farallon Capital Management LLC, according to Nexqual as of June 10, 2026 at 00:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 20.32% |
| FMR, LLC | 12.1% |
| Farallon Capital Management LLC | 9.85% |
| Arch Venture Management, Llc | 4.41% |
| Sumitomo Mitsui Trust Group, Inc. | 3.72% |
| Amova Asset Management Americas Inc | 3.72% |
| Fidelity | 3.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.15% |
| BlackRock | 10.43% |
| State Street | 9.07% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
From Beam Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
- Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
- The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.
- In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
| EDIT | Editas Medicine, Inc. | USD 2.65 | ▼ 2.21% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| CRSP | CRISPR Therapeutics AG | USD 51.48 | ▼ 0.69% |
| FATE | Fate Therapeutics, Inc. | USD 1.9 | ▼ 4.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:28 UTC. This page is informational and not investment advice.